Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Inclusion Criteria: * Body Mass Index (BMI) ≥18.5 kg/m\^2 and ≤32.0 kg/m\^2 * Under evaluation for treatment of chronic hepatitis C virus (HCV) * Chronic compensated, genotype 1 HCV infection * Treatment-naïve or previously treated and tolerated at least 12 weeks of continuous licensed interferon (including pegylated interferon) and ribavirin combination therapy with at least a partial response, or previously treated with investigational products and/or vaccines, other than HCV nonstructural proteins (NS) NS3/4A protease inhibitors, either alone or in combination with other licensed therapies * Able to avoid use of anticoagulants, nonsteroidal anti-inflammatory agents and aspirin for at least seven (7) days preceding the initial liver biopsy and continuing throughout the entire study * Female participants of childbearing potential or male participants with female sexual partners of childbearing potential must agree to use two acceptable methods of birth control from 2 weeks prior to the first dose through at least 6 months after last dose of study drug, or longer if dictated by local regulation Exclusion criteria: * Pregnant, lactating, or intending to become pregnant or donate eggs, or intending to donate sperm * History of stroke, chronic seizures, or major neurological disorder * Did not achieve a viral response to prior treatment with licensed interferon-based therapy * Previously treated with an NS3/4A protease inhibitor (investigational or licensed) * Evidence or history of chronic hepatitis not caused by HCV infection including but not limited to non-HCV viral hepatitis, nonalcoholic steatohepatitis (NASH), drug-induced hepatitis or autoimmune hepatitis * Clinical or laboratory evidence of cirrhosis or other advanced liver disease * Decompensated liver disease as indicated by a history of ascites, hepatic encephalopathy, or bleeding esophageal varices * Diagnosed with or suspected of having hepatocellular carcinoma * Co-infection with human immunodeficiency virus (HIV) * Positive hepatitis B surface antigen or other evidence of active hepatitis B infection * History of gastric bypass surgery or bowel resection * History of clinically significant uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of clinically significant neoplastic disease * Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL\], wine \[125 mL\], or distilled spirits \[25 mL\]) per day * Regular user, including use of any illicit drugs, or has a history of drug (including alcohol) abuse within the last 3 months * Surgery or donation of 1 unit of blood (approximately 500 mL) or participation in another investigational study within a period of 4 weeks prior to the prestudy (screening) visit * History of multiple and/or severe allergies, or has had an anaphylactic reaction or intolerability to prescription or nonprescription drugs or food